Titan Medical to Issue Third Quarter 2022 Financial Results on November 10, 2022
2022年11月2日 - 8:30PM
Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology
company focused on single access robotic-assisted surgery (RAS),
today announced that the company plans to issue its third quarter
2022 financial results prior to market opening on Thursday,
November 10, 2022. In addition, management will host an investor
audio webcast at 8:30 a.m. ET to discuss financial results and
business developments in the period. Speakers will include Cary
Vance, President and Chief Executive Officer, Stephen Lemieux,
Chief Financial Officer and Kristen Galfetti, VP Investor
Relations.
A link to the live audio webcast will be made available on the
"Investor Relations" section of the company’s website,
www.titanmedicalinc.com. A webcast replay will be archived and
accessible on the company’s website shortly after conclusion of the
live audio webcast.
About Titan Medical
Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device
company headquartered in Toronto, Ontario and with operations in
Chapel Hill, North Carolina, is focused on enhancing robotic
assisted surgery (RAS) using innovative technology through a single
access point. The Enos™ single-access RAS system is being developed
with an ergonomic focus to provide a surgical experience that
imitates real-life movements that surgeons demand. The Enos system
includes multi-articulating instruments designed to allow surgeons
an increased range of motion in a confined space, with dexterity
and the ability to exert the forces necessary to complete common
surgical tasks. Titan intends to initially pursue gynaecological
surgical indications with the Enos system.
Enos™ is a trademark of Titan Medical Inc.
For more information,
visit www.titanmedicalinc.com and
follow @TitanMedical on Twitter and LinkedIn.
Forward-Looking Statements
This news release contains “forward-looking statements” within
the meaning of applicable Canadian and U.S. securities laws, which
reflect the current expectations of management of the company’s
future growth, results of operations, performance and business
prospects and opportunities. Forward-looking statements are
frequently, but not always, identified by words such as “may”,
“would”, “could”, “will”, “anticipate”, “believe”, “plan”,
“expect”, “intend”, “estimate”, “potential for” and similar
expressions, although these words may not be present in all
forward-looking statements. Forward-looking statements that appear
in this release may include, without limitation, references to: the
company’s hosting of an investor audio webcast; the company’s focus
on single access robotic assisted surgery; the Enos system
providing a surgical experience that imitates real-life movements;
and the company’s intention to initially pursue gynecologic
surgical indications with the Enos system. These statements reflect
management’s current beliefs with respect to future events and are
based on information currently available to management.
Forward-looking statements involve significant risks, uncertainties
and assumptions. Many factors could cause the company’s actual
results, performance or achievements to be materially different
from any future results, performance or achievements that may be
expressed or implied by such forward-looking statements, including,
without limitation, those listed in the “Risk Factors” section of
the company’s Annual Report for the fiscal year ended December 31,
2021 (which may be viewed at www.sedar.com and at www.sec.gov).
Should one or more of these risks or uncertainties materialize, or
should assumptions underlying the forward-looking statements prove
incorrect, actual results, performance, or achievements may vary
materially from those expressed or implied by the forward-looking
statements contained in this news release. These factors should be
considered carefully, and prospective investors should not place
undue reliance on the forward-looking statements. Although the
forward-looking statements contained in the news release are based
upon what management currently believes to be reasonable
assumptions, the company cannot assure prospective investors that
actual results, performance or achievements will be consistent with
these forward-looking statements. Except as required by law, the
company expressly disclaims any intention or obligation to update
or revise any forward-looking statements whether as a result of new
information, future events or otherwise.
ContactKristen GalfettiVice President, Investor
Relations & Corporate
Communications+1-781-869-2553investors@titanmedicalinc.com
###
Titan Medical (TSX:TMD)
過去 株価チャート
から 2 2025 まで 3 2025
Titan Medical (TSX:TMD)
過去 株価チャート
から 3 2024 まで 3 2025